Oncology company Chemgenex Pharmaceuticals (CXS) is also on track again with the FDA. The company is expected to resubmit its new drug application in the first half of 2011 for Omapro, for the treatment of chronic myeloid leukaemia
http://www.asx.com.au/resources/newsletters/investor_update/20110111_9_promising_biotechs.htm